GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2006

Avalon Pharmaceuticals Commences Research on Elusive Survivin Pathway

  • Avalon Pharmaceuticals reported the start of a drug discovery program for the survivin pathway, an intractable cancer pathway. Survivin is overexpressed in multiple tumor types, including breast, lung, prostate, pancreatic, and colon. Additionally, survivin is cancer selective as it is undetectable in most normal adult cells.

    "The survivin pathway is recognized as a critical but elusive pathway for cancer therapeutics, because of its lack of enzymatic function," states David Bol, vp of pharmaceutical development at Avalon. "The survivin pathway intersects cellular networks critical for cancer cell function, including cell death, cell growth, and drug and radiation resistance."



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?